Copyright Reports & Markets. All rights reserved.

Global Arthritis Monoclonal Antibodies Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Market Analysis by Type
    • 1.3.1 Global Arthritis Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2026
    • 1.3.2 Remicade
    • 1.3.3 Humira
    • 1.3.4 Enbrel
    • 1.3.5 Rituxan
    • 1.3.6 Orencia
    • 1.3.7 Actemra
    • 1.3.8 Simponi
    • 1.3.9 Cimzia
  • 1.4 Market by Application
    • 1.4.1 Global Arthritis Monoclonal Antibodies Market Share by Application: 2020 VS 2026
    • 1.4.2 Rheumatoid Arthritis
    • 1.4.3 Osteoarthritis
    • 1.4.4 Psoriatic Arthritis
    • 1.4.5 Ankylosing Spondylitis
    • 1.4.6 Fibromyalgia
    • 1.4.7 Others
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global Arthritis Monoclonal Antibodies Market Perspective (2015-2026)
  • 2.2 Arthritis Monoclonal Antibodies Growth Trends by Regions
    • 2.2.1 Arthritis Monoclonal Antibodies Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Arthritis Monoclonal Antibodies Historic Market Share by Regions (2015-2020)
    • 2.2.3 Arthritis Monoclonal Antibodies Forecasted Market Size by Regions (2021-2026)
  • 2.3 Arthritis Monoclonal Antibodies Industry Dynamic
    • 2.3.1 Arthritis Monoclonal Antibodies Market Trends
    • 2.3.2 Arthritis Monoclonal Antibodies Market Drivers
    • 2.3.3 Arthritis Monoclonal Antibodies Market Challenges
    • 2.3.4 Arthritis Monoclonal Antibodies Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Arthritis Monoclonal Antibodies Players by Market Size
    • 3.1.1 Global Top Arthritis Monoclonal Antibodies Players by Revenue (2015-2020)
    • 3.1.2 Global Arthritis Monoclonal Antibodies Revenue Market Share by Players (2015-2020)
  • 3.2 Global Arthritis Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Arthritis Monoclonal Antibodies Revenue
  • 3.4 Global Arthritis Monoclonal Antibodies Market Concentration Ratio
    • 3.4.1 Global Arthritis Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Arthritis Monoclonal Antibodies Revenue in 2019
  • 3.5 Key Players Arthritis Monoclonal Antibodies Area Served
  • 3.6 Key Players Arthritis Monoclonal Antibodies Product Solution and Service
  • 3.7 Date of Enter into Arthritis Monoclonal Antibodies Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Arthritis Monoclonal Antibodies Breakdown Data by Type

  • 4.1 Global Arthritis Monoclonal Antibodies Historic Market Size by Type (2015-2020)
  • 4.2 Global Arthritis Monoclonal Antibodies Forecasted Market Size by Type (2021-2026)

5 Arthritis Monoclonal Antibodies Breakdown Data by Application

  • 5.1 Global Arthritis Monoclonal Antibodies Historic Market Size by Application (2015-2020)
  • 5.2 Global Arthritis Monoclonal Antibodies Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Arthritis Monoclonal Antibodies Market Size (2015-2026)
  • 6.2 North America Arthritis Monoclonal Antibodies Market Size by Type (2015-2020)
  • 6.3 North America Arthritis Monoclonal Antibodies Market Size by Application (2015-2020)
  • 6.4 North America Arthritis Monoclonal Antibodies Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Arthritis Monoclonal Antibodies Market Size (2015-2026)
  • 7.2 Europe Arthritis Monoclonal Antibodies Market Size by Type (2015-2020)
  • 7.3 Europe Arthritis Monoclonal Antibodies Market Size by Application (2015-2020)
  • 7.4 Europe Arthritis Monoclonal Antibodies Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Arthritis Monoclonal Antibodies Market Size (2015-2026)
  • 8.2 Asia-Pacific Arthritis Monoclonal Antibodies Market Size by Type (2015-2020)
  • 8.3 Asia-Pacific Arthritis Monoclonal Antibodies Market Size by Application (2015-2020)
  • 8.4 Asia-Pacific Arthritis Monoclonal Antibodies Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia

9 Latin America

  • 9.1 Latin America Arthritis Monoclonal Antibodies Market Size (2015-2026)
  • 9.2 Latin America Arthritis Monoclonal Antibodies Market Size by Type (2015-2020)
  • 9.3 Latin America Arthritis Monoclonal Antibodies Market Size by Application (2015-2020)
  • 9.4 Latin America Arthritis Monoclonal Antibodies Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Arthritis Monoclonal Antibodies Market Size (2015-2026)
  • 10.2 Middle East & Africa Arthritis Monoclonal Antibodies Market Size by Type (2015-2020)
  • 10.3 Middle East & Africa Arthritis Monoclonal Antibodies Market Size by Application (2015-2020)
  • 10.4 Middle East & Africa Arthritis Monoclonal Antibodies Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE

11Key Players Profiles

  • 11.1 AbbVie Inc
    • 11.1.1 AbbVie Inc Company Details
    • 11.1.2 AbbVie Inc Business Overview
    • 11.1.3 AbbVie Inc Arthritis Monoclonal Antibodies Introduction
    • 11.1.4 AbbVie Inc Revenue in Arthritis Monoclonal Antibodies Business (2015-2020))
    • 11.1.5 AbbVie Inc Recent Development
  • 11.2 F. Hoffmann-La Roche Ltd
    • 11.2.1 F. Hoffmann-La Roche Ltd Company Details
    • 11.2.2 F. Hoffmann-La Roche Ltd Business Overview
    • 11.2.3 F. Hoffmann-La Roche Ltd Arthritis Monoclonal Antibodies Introduction
    • 11.2.4 F. Hoffmann-La Roche Ltd Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.2.5 F. Hoffmann-La Roche Ltd Recent Development
  • 11.3 Novartis
    • 11.3.1 Novartis Company Details
    • 11.3.2 Novartis Business Overview
    • 11.3.3 Novartis Arthritis Monoclonal Antibodies Introduction
    • 11.3.4 Novartis Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.3.5 Novartis Recent Development
  • 11.4 Johnson & Johnson(Janssen)
    • 11.4.1 Johnson & Johnson(Janssen) Company Details
    • 11.4.2 Johnson & Johnson(Janssen) Business Overview
    • 11.4.3 Johnson & Johnson(Janssen) Arthritis Monoclonal Antibodies Introduction
    • 11.4.4 Johnson & Johnson(Janssen) Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.4.5 Johnson & Johnson(Janssen) Recent Development
  • 11.5 Pfizer Inc
    • 11.5.1 Pfizer Inc Company Details
    • 11.5.2 Pfizer Inc Business Overview
    • 11.5.3 Pfizer Inc Arthritis Monoclonal Antibodies Introduction
    • 11.5.4 Pfizer Inc Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.5.5 Pfizer Inc Recent Development
  • 11.6 Mylan
    • 11.6.1 Mylan Company Details
    • 11.6.2 Mylan Business Overview
    • 11.6.3 Mylan Arthritis Monoclonal Antibodies Introduction
    • 11.6.4 Mylan Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.6.5 Mylan Recent Development
  • 11.7 Genentech
    • 11.7.1 Genentech Company Details
    • 11.7.2 Genentech Business Overview
    • 11.7.3 Genentech Arthritis Monoclonal Antibodies Introduction
    • 11.7.4 Genentech Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.7.5 Genentech Recent Development
  • 11.8 GSK
    • 11.8.1 GSK Company Details
    • 11.8.2 GSK Business Overview
    • 11.8.3 GSK Arthritis Monoclonal Antibodies Introduction
    • 11.8.4 GSK Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.8.5 GSK Recent Development
  • 11.9 AstraZeneca PLC
    • 11.9.1 AstraZeneca PLC Company Details
    • 11.9.2 AstraZeneca PLC Business Overview
    • 11.9.3 AstraZeneca PLC Arthritis Monoclonal Antibodies Introduction
    • 11.9.4 AstraZeneca PLC Revenue in Arthritis Monoclonal Antibodies Business (2015-2020)
    • 11.9.5 AstraZeneca PLC Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Arthritis Monoclonal Antibodies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Arthritis Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Remicade
    Humira
    Enbrel
    Rituxan
    Orencia
    Actemra
    Simponi
    Cimzia

    Market segment by Application, split into
    Rheumatoid Arthritis
    Osteoarthritis
    Psoriatic Arthritis
    Ankylosing Spondylitis
    Fibromyalgia
    Others

    Based on regional and country-level analysis, the Arthritis Monoclonal Antibodies market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    In the competitive analysis section of the report, leading as well as prominent players of the global Arthritis Monoclonal Antibodies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    AbbVie Inc
    F. Hoffmann-La Roche Ltd
    Novartis
    Johnson & Johnson(Janssen)
    Pfizer Inc
    Mylan
    Genentech
    GSK

    Buy now